EP4353222A1 — Use of sodium alkyl sulfate
Assigned to Taiho Pharmaceutical Co Ltd · Expires 2024-04-17 · 2y expired
What this patent protects
The present invention is directed to the use of sodium lauryl sulfate in the production of a pharmaceutical composition comprising (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl-1-pyrrolidinyl)-2-propen-1-one, which is effective as an antitumor…
USPTO Abstract
The present invention is directed to the use of sodium lauryl sulfate in the production of a pharmaceutical composition comprising (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl-1-pyrrolidinyl)-2-propen-1-one, which is effective as an antitumor agent. The sodium lauryl sulfate improves the absorption and the manufacturability (lubricative property/flowability) of the pharmaceutical composition. Also provided is a method of manufacturing a pharmaceutical composition comprising (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl-1-pyrrolidinyl)-2-propen-1-one, the method comprising a step of adding sodium lauryl sulfate.
Drugs covered by this patent
- Lytgobi (futibatinib) · Taiho Oncology
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.